Compare Eli Lilly And Co (LLY) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs uniQure N.V. Ordinary Shares — how do they compare? Eli Lilly And Co trades at $1,231.9 (market cap $1.08T), while uniQure N.V. Ordinary Shares trades at $20.71 (market cap $1.45B). The key difference: Eli Lilly And Co is far larger — about 744.8× uniQure N.V. Ordinary Shares's market cap, and Eli Lilly And Co pays a 0.57% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 94 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| LLY | QURE | |
|---|---|---|
Market Cap | $1.08T | $1.45B |
Volume | 2,520,401 | 3,323,243 |
Sector | Health | Health |
52-Week High | $1.28K | $70.59 |
52-Week Low | $799.57 | $9.03 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $1.12T | $707.46M |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,166.51, down 1.36% on the day, amid strong fundamentals with revenue surging to $65.18B in 2025 and net income reaching $20.64B. The stock exhibits a bullish technical trend, supported by moving averages, with key resistance near $1,190. Recent news highlights promising pipeline developments in weight-loss drugs, reinforcing growth prospects.
Outlook remains positive given robust earnings beats, high analyst buy ratings (73%), and a consensus price target of $1,350. Risks include competitive pressures and execution challenges in scaling production. The stock's premium valuation (P/E 39.16) warrants monitoring, but strong cash flow and innovation pipeline support long-term upside.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
